http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
IX, 377 p. 28 illus., 15 illus. in color. online resource.
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.
Preface: Tribute to J Waldenström -- Part I: Tumor Cells and microenvironment -- Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment -- Waldenström’s Macroglobulinemia Immunophenotype -- Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis -- Cytogenetics in Waldenstr<öm Macroglobulinemia (WM) -- Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia -- Molecular Pathways in Growth and Survival: Epigenomics -- The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia -- Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment -- Part II: Epidemiology and Genetic Predisposition -- Epidemiology of Waldenström Macroglobulinemia -- Genetic Predisposition to Waldenström Macroglobulinemia -- Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) -- Part III: Clinical Features -- Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia -- Neuropathy in Waldenström’s Macroglobulinaemia -- IgM Amyloidosis -- The Bing-Neel Syndrome -- Unusual Manifestations of IgM Monoclonal Gammopathies -- Part IV: Laboratory Investigations -- Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains -- Part V: Response -- Response Assessment in Waldenström’s Macroglobulinaemia -- Part VI: Prognostic Factors -- Risk Stratification in Waldenström Macroglobulinemia -- Part VII: Treatment Options and Recommendations -- Indications for Treatment of Waldenström’s Macroglobulinemia -- Immunotherapy in Waldenström’s Macroglobulinemia -- Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia -- Signal Inhibitors in Waldenström’s Macroglobulinemia -- High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia -- Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia -- Treatment Recommendations in Waldenström Macroglobulinemia.
edited by Véronique Leblond, Steve Treon, Meletios Dimoploulos.